Wednesday, December 26, 2018 2:59:19 PM
HC Wainwright Bullish On Corbus Therapeutics' Cystic Fibrosis Opportunity
Priya Nigam , Benzinga Staff Writer December 26, 2018 11:50am
Corbus Pharmaceuticals Holdings Inc CRBP 5.71% has Phase 3 trials ongoing for its lead compound lenabasum in systemic sclerosis and dermatomyositis, and Phase 2 trials for cystic fibrosis and systemic lupus erythematosus.
With cannabinoid receptor type 2 being a critical component of resolution following inflammation, there could be “significant readthrough from one indication to the next,” according to H.C. Wainwright.
The Analyst
Analyst Andrew Fein initiated coverage of Corbus Pharmaceuticals with a Buy rating and $24 price target.
The Thesis
Although success in systemic sclerosis or dermatomyositis alone may be insufficient to lend upside to Corbus Pharmaceuticals’ shares, there is potential in lenabasum’s ability to address inflammation in cystic fibrosis, Fein said in the Wednesday initiation note.
Cystic fibrosis patients experience chronic inflammation that results in a decline in lung function, and the disease is strongly associated with more frequent pulmonary exacerbations and morbidity.
While Vertex Pharmaceuticals Incorporated
VRTX 4.05%'s triple therapies may make modulator therapy available for nearly 90 percent of those with a CF mutation, modulators of the cystic fibrosis transmembrane conductance regulator are unlikely to fully reverse the structural damage in CF patients, the analyst said.
A need exists for anti-inflammatory therapy in the cystic fibrosis space, Fein said, adding that addressing the resolution phase could offer a new approach. Lenabasum provides "the most advanced agent to target resolution," he said.
https://www.benzinga.com/analyst-ratings/analyst-color/18/12/12899545/hc-wainwright-bullish-on-corbus-therapeutics-cystic-fib
Recent CRBP News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:00:13 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/08/2024 08:03:35 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2024 08:35:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 12:30:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 10:13:33 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 10:07:02 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:45:24 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 09:41:54 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 09:08:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 08:19:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/06/2024 09:12:51 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/05/2024 09:47:34 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/05/2024 09:21:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/05/2024 01:12:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 10:27:41 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/01/2024 10:09:08 PM
- Form S-3MEF - Registration adding securities to prior Form S-3 registration [Rule 462(b)] • Edgar (US Regulatory) • 01/31/2024 02:16:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/30/2024 09:56:07 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 01/29/2024 09:40:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/29/2024 12:31:08 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/29/2024 12:30:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/26/2024 12:47:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/09/2024 01:45:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 10:25:47 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/07/2023 09:57:41 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM